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ENGINEERING A PROPHYLACTIC CAP FOR MULTI-DOSE VIAL 
DISINFECTION  
2020-2021 
Erik Christopher Brewer, Ph.D. 
Master of Science in Biomedical Engineering 
 
Recently, multi-dose vials (MDVs) have demonstrated significant bioburden, with 
randomized studies revealing bacterial contamination rates up to 27%. When the proper 
protocol of disinfecting the vial diaphragm with a pre-saturated wipe is followed, MDV 
bioburden is eliminated. However, when this sterilization protocol is neglected, the 
susceptibility of MDV to house potential nosocomial pathogens intensifies. In this work, 
the usability and effectiveness of a novel device, referred to as the Vial Cap, are 
investigated to gauge the feasibility and acceptability of this device as a method of MDV 
disinfection. The usability of the Vial Cap was evaluated using principle human factors 
engineering (HFE) techniques to quantify the device’s ease of use, efficiency, and user 
acceptance. The Vial Cap was observed to be highly accepted by the intended users as 
represented by a high System Usability Scale (SUS) score. The Vial Cap was significantly 
more efficient in simulated timed-based studies and the users were able to easily to operate 
the device. Specific elements of the Vial Cap were evaluated to determine their individual 
impact on disinfection efficacy. The minimum disinfection time, applied force, and 
estimated usage were evaluated to determine improvements to the Vial Cap design. 
Implementation of design recommendations from this research can produce a Vial Cap that 
can enhance MDV disinfection practices and increase patient safety. 
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1.1 Research Motivation 
Nosocomial infections are a burden on hospitals with an estimated incidence of 4.5 
infections per 100 hospital admissions and an annual cost of $45 billion [1]. In the United 
States (US), approximately 2 million patients will develop a nosocomial infection and 
about 90,000 of these patients die [1], [2]. Nosocomial infections, or hospital-acquired 
infections (HAIs) are illnesses patients acquire during their stay at the hospital that were 
not present at the time of admission [3]. These infections are contracted through contact 
with contaminated medical equipment, airborne droplets, direct patient contact, or 
improper hand washing of healthcare personnel. The presence of these infections is 
unceasing with occurrence rates in 5-10% of all hospitals in Europe and North America, 
and more than 40% in parts of Asia, South America, and sub-Saharan Africa [3].   
Recently, multi-dose vials (MDVs) have demonstrated significant bioburden, with 
randomized studies revealing bacterial contamination rates up to 27% [4]. Potentially 
pathogenic microorganisms, like bacteria, viruses, and fungi, can survive and even 
proliferate in and on MDV’s, increasing the risk of infection [5]. For example, outbreaks 
of pyogenic abscesses occurred after diphtheria, tetanus toxoids, and pertussis (DTP) 
vaccinations that were contaminated with group A Streptococcus and Staphylococcus (S.) 
aureus [6].  
Established disinfection protocols are utilized for injection preparation that involve 




recognized disinfection protocols, studies note that poor aseptic technique due to user error 
is a common cause of vial contamination that is responsible for considerable morbidity and 
mortality [8], [9]. In a study conducted at a tertiary care hospital, it was observed that 
98.7% (n = 307) of the vial rubber diaphragm were not swabbed with alcohol in compliance 
with the current disinfection protocol [9]. Personal neglect of proper disinfection protocols 
is a mounting issue with MDV preparation and administration. There is an ensuing need 
for implementation of improved MDV decontamination methods that can mitigate user 
errors and ensure continuous vial disinfection.  
1.2 Project Scope   
The aim of this research is to assess elements of an innovative device (referred to 
as the Vial Cap) that curtails user error involving MDV disinfection and reduces the risk 
of vial-associated nosocomial infections. All aspects of the Vial Cap prototype design have 
been engineered with two basic requirements: 1) the Vial Cap must be effective and 2) the 
Vial Cap must have sufficient usability. To limit vial-related infection outbreaks such as 
hepatitis C, meningitis, and sepsis, the Vial Cap must be effective against pathogenic 
microorganisms [6], [10]. Usability is also another important device characteristic that can 
appraise the feasibility of the Vial Cap as a method of MDV sterilization. Development of 
a device from a human factors-perspective can enhance aspects of the design that increase 
its efficiency and usability [11], [12]. These design criteria will be explored through human 
factor engineering (HFE) assessment techniques and standard engineering protocols to 






2.1 Nosocomial Infections  
In recent years, the incidence of HAIs in the US has increased by 36% with an 
annual occurrence of over 2.1 million cases [2], [13]. The World Health Organization 
(WHO) estimates that approximately 15% of all hospitalized patients suffer from 
nosocomial infections [14]. An HAI is defined as an infection that develops 48 hours after 
hospital admission or discharge [15]. Common HAIs include hepatitis, septicemia, soft-
tissue infections, and respiratory tract infections [15]. At-risk individuals with preexisting 
conditions such as diabetes or immunosuppression and patients in Intensive Care Units 
(ICUs) are 5-10 times more likely to acquire an HAI [14], [16], [17]. Risk factors that 
determine HAI outbreaks depend upon the environment, condition of the patient, and 
healthcare worker compliance with infection control methods [14]. Common modes of 
transmission for nosocomial pathogens include contaminated medical equipment, direct 
contact with an infected individual, or environmental sources such as water or body fluids.  
 HAIs are among the top five leading causes of death in the United States [1]. This 
brings both a clinical and economic burden to hospitals and patients alike. In a study about 
the impact of HAIs based on data from the Healthcare Cost and Utilization Project, it was 
found that the mortality rates, length of hospital stay, and medical costs of patients with 
HAIs were significantly higher compared to patients without HAIs [1]. Patients with HAIs 
had costs that were 2.5-fold higher and a mortality rate that was 1.9-fold higher compared 




antimicrobial resistance, socio-economic disturbance, and mortality rates can all be related 
to the occurrence of a nosocomial infection [14]. In a study of New York City hospitals, S. 
aureus infections prolonged the length of stay an additional 20 days, accruing a total direct 
cost of $32,100 per patient [18]. The CDC estimates that the overall annual direct costs 
associated with nosocomial infections range from $35.7 to $45 billion [13]. This economic 
burden drives the need for improved infection prevention programs in hospitals and 
outpatient care facilities.  
To date, it is uncertain what percentage of nosocomial infections are avoidable 
under real-life hospital conditions. However, countless studies have proven the viability of 
implementing infection control programs and HAI surveillance to reduce the infection rate 
[19]–[21]. Surveillance of nosocomial infections can be used to assess the quality of care 
in the hospital and the epidemiology of a nosocomial pathogen. For example, surveillance 
data shows that Escherichia (E.) coli infections are found in 25% of urinary tract infections 
(UTIs) while Pseudomonas (P.) aeruginosa is more commonly isolated from all major 
infection sites except the blood stream [3]. The effectiveness of nosocomial infection 
surveillance has proven to reduce infection rates anywhere from 14% to 71% [19].  
HAI transmission from improper injection techniques and unawareness or personal 
neglect of infection control measures are often the result of poor compliance with 
established infection control methods [8], [14]. For example, the most preventable type of 
HAI, central line-associated blood stream infections (CLABSIs), are commonly spread 
through direct contact with proliferating bacteria on medical equipment and hard surfaces 
that were not properly disinfected [22]. Infection control methods that can significantly 




isolation of infected individuals, and decontamination of high-touch surfaces [23]. In a 
study conducted at an university hospital in East Germany, it was found that 12-17% of 
HAIs were classified as easily avoidable and 52-55% of cases were considered avoidable 
under theoretical situations [19]. Greater than 50% of device-associated bloodstream 
infections are also avoidable when proper disinfection practices are followed [19]. 
Implementation of mandatory infection control protocols and increased healthcare worker 
compliance has proven to significantly reduce infection rates and patient mortality [23].  
2.1.1 Nosocomial Pathogens 
 The hospital microenvironment has the potential to house thousands of nosocomial 
pathogens on contaminated surfaces, in the environment, and in pathogenic patients [24]. 
Pathogens responsible for HAIs include bacteria, viruses, and fungal spores. Specifically, 
Gram-positive bacteria are the most common cause of nosocomial infections with S. aureus 
being the predominant pathogenic species [25]. In a study conducted at a government 
hospital in Nigeria, it was found that 80.4% of isolate microorganisms were Gram-positive 
bacteria, with Staphylococcus epidermis and S. aureus being the most frequent [24]. Other 
notable pathogens that can survive in dry environments include Clostridium difficile, 
methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter baumannii, P. 
aeruginosa, and norovirus [26], [27].  
The most relevant nosocomial pathogens persist on hard surfaces for months and 
can even proliferate into antimicrobial resistant pathogens. Antimicrobial resistant 
pathogens, like MRSA, create a serious risk for high-transmission and mortality rates 




of samples from infected patients have a survival rate of 44% even after bleach disinfection 
[27]. The rates of nosocomial pathogen survival are a direct correlation to the 1.7 million 
occurrences of HAIs per year [29]. The importance of proper disinfection procedures, 
products, and compliance all play equally significant roles in the prevention of HAIs. Use 
of effective and efficient disinfection practices is a viable solution to diminishing the 
frequency and mortality of HAIs.  
2.1.2 Disinfection Practices 
 The persistence of bacterial survival on hard surfaces is a concern for HAI 
outbreaks. The combination of potential bacterial proliferation and poor surface 
disinfection creates an opportunity to propagate nosocomial infections [30]. When proper 
disinfection protocol is practiced, HAIs can effectively be eradicated from a contaminated 
surface and reduce the risk of further transmission [30]. Variability due to human factors 
such as user compliance, acceptance, awareness, and accessibility can affect disinfection 
efficacy [30]. Studies using fluorescent markers to monitor disinfection practices have 
demonstrated that some required surfaces and high-touch surfaces are not completely 
decontaminated due to lack of compliance or unawareness [30], [31].  
 Aside from hard surfaces, reusable medical equipment can also be a mode of 
transmission for nosocomial pathogens when improper disinfection occurs. For example, 
unsterile injections result in 8 to 16 million new infections of Hepatitis B worldwide [32]. 
Vaccinations with MDVs in developing countries has been linked to high transmission of 
HAIs due to poor infection control measures [14], [32], [33]. Contamination rates of 80% 




disinfection with alcohol pads prior to use [29]. The crucial role of wiping non-invasive 
medical equipment with alcohol pads or other disinfectants is highlighted in numerous 
studies by astonishing contamination rates as high as 94% [33]. 
The first step in successful disinfection is the selection of the ideal disinfectant. The 
Environmental Protection Agency (EPA) has rigorous testing guidelines that disinfectants 
must undergo to be deemed ‘effective’ for hospital-level disinfection [34]–[36]. 
Compliance with healthcare and cleaning staff is also another important aspect of proper 
disinfection. Observational methods have shown that individual housekeeper performance 
varies considerably where only 40-50% of surfaces are disinfected [37]. Continuing efforts 
are needed to improve the quality and consistency of surface disinfection. The monitoring 
and reporting of HAI incidence, cleaning logs, implementation of modern technologies, 
and continuing education of healthcare staff have all proven to effectively reduce the 
occurrence of HAIs [31], [37], [38].  
2.2 MDV Contamination 
MVDs typically contain antimicrobial preservatives that help prevent the growth of 
potential nosocomial pathogens that remain effective for 28 days [6]. However, these 
preservatives are only effective when proper vial disinfection protocol is followed [39]. It 
is well documented that MDV contamination is a prominent problem in the healthcare 
field. It has been reported that the rate of MDV extrinsic contamination is estimated to 
range from 0% to 27% [40]. In developing countries, at least 50% of injections from MDVs 
are unsafe due to poor injection practices [41]. At least 17 studies have reported MDV-




albicans, S. aureus, and hepatitis viruses [4]. Factors that may affect the sterility of MDVs 
include the number of withdrawals, sterility techniques employed by healthcare personnel, 
duration of storage, injection environment, and the viability of present antimicrobial 
preservations [42].  
When used properly, MDVs offer a cost-effective injection method in a healthcare-
setting compared to single-dose vials (SDVs) [43], [44]. SDVs are preservative-free 
medications that contain only a single dose of medication. They are intended for use for 
one patient and should remain sealed until administration. However, SDVs have shown 
contamination rates of 5.4% (n = 165) as a result of use for multiple patients [10]. 
Miscommunication in medical practices, inadequate training, and user negligence can all 
result in SDV contamination [44].  
The proper MDV disinfection protocol (referred to as the Gold Standard) generally 
involves the disinfection of the vial rubber diaphragm with a pre-saturated wipe before 
piercing. According to the CDC, WHO, and the Joint Commission, the Gold Standard (GS) 
procedure requires that a 70% IPA wipe or swab be used to wipe the vial septum and allow 
to dry for minimum 30 seconds before piercing [45]–[47]. Single-use swabs or pre-
saturated towelettes should only be used for MDV disinfection [48]. In other countries, 
national guidelines for MDV use are sometimes nonexistent, increasing the risk of 
infections [49]. Often a single MDV that was improperly decontaminated can be the root 




2.2.1 User Compliance 
A main source of MDV contamination can be related to user error in sterility 
techniques when withdrawing medication from a MDV [8]. In a pilot study conducted at a 
super-specialty hospital, a contamination rate of 25% were found among the sampled vials 
[8]. This study aimed to evaluate the common knowledge and practices of nursing staff 
regarding MDVs. It was found that the rubber diaphragms of many MDVs were never 
disinfected with isopropyl alcohol (IPA) prior to use [8]. In a teaching hospital in Shiraz, 
Iran, MDV contamination rates of 5.6% were attributed to lack of vigorous aseptic 
precautions and enforcement of mandatory practices [40]. Although guidelines from 
professional organizations like the CDC and WHO are in place for injection safety, it does 
not ensure the opportunity of user-related errors is diminished [30], [50].   
Other user compliance-related issues with MDV disinfection include reusing 
needles or syringes, leading to serious outbreaks of HAIs including 20 million cases 
annually of hepatitis B (HBV) and 2 million hepatitis C (HCV) cases [48]. Incidence of 
improper preparation of the skin for an injection with a pre-saturated towelette or iodine 
can also increase the chance for infection [9], [48], [51]. These poor injection practices are 
vastly addressed in guidelines by the CDC and the WHO, however, issues related to MDV 
disinfection are lesser addressed as there is a push to use SDVs or MDVs for one patient 
[45], [51]–[53]. In developing countries, MDVs are a vital part of their healthcare system 
because of they are cost-effective when used properly [54], [55]. Therefore, it is necessary 
that MDV disinfection practices improve in order to reduce the opportunity for user-related 





2.3 Current Solutions  
2.3.1 MDV Alternatives 
According to the CDC, multi-dose vials should be dedicated to a single patient 
whenever possible [53]. Yet, this can be wasteful as MDVs contain more than one dose per 
vial and medication costs are ever increasing [39]. SDVs are a potential solution for MDVs 
to reduce medication waste in instances when an MDV is restricted to one patient. 
However, prevalence of SDV extrinsic contamination has been reported with rates as high 
as 5.6% with bacterial and fungal pathogens [10], [40]. SDVs are also associated with 
increased wastage, manufacturing, packaging, and usage costs [54]. SDV misuse can also 
result in higher rates of infection because these medications do not contain antimicrobial 
preservatives.  
 Pre-filled syringes are a more recent development that have been adopted in 
hospitals to replace SDVs and MDVs [57], [58]. Pre-filled syringes contain a single dose 
of medication that requires little to no overfill volume. The advantages of pre-filled 
syringes are the reduction of waste and reduced risk of contamination [57]. However, the 
manufacturing and production costs of pre-filled syringes is significantly higher, ranging 
anywhere from $5-30 per unit compared to $2.40 per 10-dose MDV [57]. User compliance 
is still an occurring issue with the use of pre-filled syringes. In a study conducted 
comparing pre-filled syringes to self-filled syringes, several patients experienced 
difficulties with injecting the entire solution, difficulty activating the injection, and that the 




2.3.2 MDV Disinfection Caps 
In the effort to maintain usage of MDVs, caps have been engineered to provide 
protection of a vial during use and storage. Thomas et al. invented a patented device called 
a ‘Reusable Vial Cap’ (Figure 1). The intended use of this device is to create a reusable 
sealed closure that takes place of the crimped aluminum cap on a standard MDV [61]. This 
cap is made from a resilient plastic material that clamps onto a MDV vial over the rubber 
diaphragm [61]. The intentions of this design are only to replace the crimped aluminum 
cap and protect atmospheric debris from collecting on the vial during storage [61].  
 
Figure 1 
Diagram of Invention US Patent no. 4,480,762 
 
 
Another invention by Storar et al. was a plastic cap with a plastic hinge integrally 
connected to provide closure to the vial during storage (Figure 2). A central opening on the 
cap is provided to allow for a hypodermic needle to penetrate the MDV during an injection 




not provide chemical disinfection and still allow for the opportunity of  MDV 
contamination when disinfection is neglected.  
 
Figure 2 
Diagram of Invention US Patent no. 5,088,612 
 
 
The Vial Cap is a proposed patent-pending design, entitled ‘Reloadable Antiseptic 
Vial,’ that has been engineered to be a disinfecting cap for MDVs (Figure 3) [63]. An ideal 
disinfecting cap for MDVs would provide continuous chemical disinfection, a physical 
barrier against pathogens, and be easy and efficient to operate. The Vial Cap incorporates 
these design criteria into integral cap design that provides continuous sterilization of an 
MDV during use and storage. The patent-pending design proposed two variations of the 
device related to its reusability. The first proposal is a sterile, single-use cap design that is 
made from a nonporous plastic [63]. The second proposed design is a reusable cap that 
disinfects a MDV vial between uses by housing a replaceable pre-saturated sponge or 




The proposed usage and design from Provisional Patent no. 62/496,676 were used in 
reference for the current iteration of the Vial Cap design.  
 
Figure 3 
Patent-Pending Design of the Vial Cap 
 
 
2.4 Vial Cap Design 
2.4.1 Human Factors Engineering 
 With the advancement of technologies in medicine, important considerations for 
patient safety while maintaining efficiency and effectiveness are at the forefront of 
engineering design [64]. HFE is a discipline of engineering that seeks to support device 
and system development with the central focus based around the user [65]. HFE design is 
devoted to optimizing the design of a device that improves device performance and user 




training time, increased ease of use, improved task performance, and enhanced patient and 
user satisfaction [11].  
 HFE best practices were utilized throughout the design validation of the current 
Vial Cap prototype. User research played an integral role in the Vial Cap design because 
there is an evident need for a more efficient method of MDV disinfection that reduces the 
opportunity for user-errors [52], [66], [67]. Usability testing was conducted to allow for 
the intended users to interact with the current Vial Cap prototype. Usability testing is a 
formal method of systemically observing users that allows for the ease of use, ease of 
learning, efficiency, and user appeal to be assessed [11], [12], [68]. Utilizing these HFE 
techniques during the Vial Cap design process can be used to enhance future device 
performance and improve user safety and satisfaction [65], [68], [69].  
2.4.2 Design Criteria 
The design criteria of the Vial Cap can be summarized by two requirements: The 
Vial Cap must be effective and have sufficient usability. An effective Vial Cap is defined 
by its ability to disinfect nosocomial pathogens with comparable metrics to pre-saturated 
wipes [70]. Without achieving the minimal disinfection requirements of pre-saturated 
wipes, the Vial Cap will not be an approved device for use [70], [71]. The other important 
aspect of interest is usability. Usability metrics such as learnability and efficiency can help 





2.4.3 Design Iterations 
The Vial Cap design was influenced by the provisional patent to provide consistent 
disinfection of MDVs during use and storage that allows for immediate medication 
withdraw after cap removal. The basics of the Vial Cap design incorporate a physical 
barrier made from polylactic acid (PLA), a ridge plastic used in 3-dimensional (3D) 
printing. Housed inside the cap is a cotton sponge saturated with 70% IPA to act as a 
chemical disinfectant. The progression of the Vial Cap design reflects evolving HFE design 
considerations for the intended users and operation of the device.  
3D printing was used as the iterative prototyping method for the scope of this 
research. 3D Printing is a manufacturing method in which objects are made by depositing 
materials in layers to produce a 3D object [72]. This additive manufacturing method allows 
for the rapid and cost-effective development of products [72]–[74]. A Creality Ender 3 Pro 
equipped with Inland PLA and PLA+ filament was used for cap prototypes. A ridge, 
nonporous plastic filament was selected for the Vial Cap design because of its ability to 
withstand any damage during storage and use. The key printing parameters can be found 










3D Printing Parameters 
Parameter Input 
Infill 100% 
Number of Shells 4 
Layer Height 0.2 mm 
Extruder Temperature 210°C 
Printing Speed 60 mm/s 
 
The Vial Cap design history can be defined with four generations of 3D printed 
prototypes. The first-generation design of the Vial cap was created to gain an understanding 
of the vial dimensions (Figure 4). This first design was engineered to seal the diaphragm 
of the vial from the environment, similar to patented vial cap designs [61], [62]. The design 
also included ridges on the outside of the cap to provide traction for user ease of use. This 










First-Generation Vial Cap Design 
 
Note. A) Vial Cap render. B) Modeling of first-generation Vial Cap.  
 
Second-generation cap design iterations included an increased cap height that 
allows for a pre-saturated sponge to be housed (Figure 5). Complications with this cap 
design that prohibited its success were issues related to pressing the cap on to seal it. There 
is no mechanism that prevents the user from pressing the cap flush with an MDV, and as a 












Second-Generation Vial Cap Design 
 
Note. A) Vial Cap render. B) Modeling of second-generation Vial Cap. 
 
 For the third-generation cap design, the height was decreased, and an inner ridge 
was incorporated into the cap design to house the sponge (Figure 6). The inner ridge served 
dual purposes: to act as a ledge to house the sponge and prevent the user from forcing the 
cap on too far. However, a significant usability flaw with this design is the potential for 












Third-Generation Vial Cap Design 
 
Note. A) Vial Cap render. B) Modeling of third-generation Vial Cap. C) Birds-eye view of 
the inner ridge of the Vial Cap. 
 
2.4.4 Current Vial Cap Design 
The current Vial Cap design, also considered the fourth-generation design, 
incorporates an integral hinge design that resolves the issues of the previous cap designs 
(Figure 7). The hinge design allows for the cap to easily open during an injection while 
remaining attached to the MDV. The cap maintained the inner ridge design to house the 
sponge and prevent any issues with sealing the cap. Additionally, a tab was added to the 










Fourth-Generation Vial Cap Design 
 
Note. A) Vial Cap render, side-view. B) Vial Cap render, open cap C, D) Modeling of 
fourth-generation Vial Cap.  
 
HFE design techniques were used to engineer this optimal cap design that 
incorporates all aspects of the other designs to improve overall usability and efficiency 
(Figure 8) [11], [75]. For the focus of this research, the fourth-generation cap design was 
used to assess the effectiveness and usability of the Vial Cap.  
 
Figure 8 
Vial Cap Design Generations 
 
Note. A, B) Modeling of Vial Cap design generations.  








This work focuses on assessing different elements of the Vial Cap prototype design 
that will achieve the required levels of disinfection and have acceptable usability. Design 
requirements associated with disinfection and usability are the main motivators of this 
research because they summarize the main issue with MDV contamination: user error with 
the current disinfection protocol. Therefore, determining the cap elements that maximize 
effectiveness and usability can ensure the device is more readily accepted by the intended 
users for implementation in a hospital setting.  
The first objective was to assess the usability of current Vial Cap prototype to 
understand what cap elements allow the device to be efficient to operate, easy to use, and 
yield high user acceptability. Human factors methods were used to design and execute a 
usability assessment of the Vial Cap to reveal any design flaws and receive user feedback 
about the current prototype design [76]. Measurable outcomes such as the error rate, 
completion rate, and timed operation were quantified to determine which elements of the 
current design can be improved.  
The second objective was focused on determining the design elements that enhance 
the sterilization capabilities of the Vial Cap. ASTM Standard E2362-15, which defines a 
standard method to evaluate the hard surface disinfection of pre-saturated towelettes, was 
modified for testing the Vial Cap’s effectiveness. Instead of disinfecting a hard surface, the 
test specimen were cultured on the rubber vial septum for disinfection [71]. The selected 




nosocomial pathogens [78], [79]. Aspects of the Vial Cap design such as disinfection time, 
applied force, and sponge saturation were studied using to determine future cap design 
iterations and estimate standards for labeling.  
The specific aims of this project are as follows: 
Specific Aim 1: Assess the acceptability of the Vial Cap prototype based on a usability test 
designed to measure its ease of use, efficiency, and user satisfaction.  
Specific Aim 2: Evaluate design elements of the Vial Cap prototype and their impact on its 












Usability Assessment of the Vial Cap 
4.1 Introduction  
Human factors engineering is the application of knowledge about human abilities 
(physical, intellectual, sensory) and limitations to the design and manufacturing of devices, 
systems, and organizations [11]. HFE involves the combination of behavioral studies and 
engineering principles in device design and evaluation [11]. One of the main goals of HFE 
design is usability. Usability is defined as the extent to which a product can be easily used 
by the intended users to achieve certain goals with effectiveness, efficiency, and 
satisfaction [80], [81]. Device design without the use of HFE techniques can increase the 
risk of injury, training time, decrease the ease of use, and diminish user satisfaction [11]. 
The Harvard Medical Practice Study showed that human error is the cause of up to 69% of 
injuries to patients related to medical devices [82]. Hence, it is important that HFE-based 
design and assessments are utilized to evaluate usability aspects of the Vial Cap design. 
A usability test was designed to test the ease of use, efficiency, and user satisfaction 
of the Vial Cap prototype. Efficiency was measured by comparing how long it takes the 
user to disinfect an MDV using the Vial Cap compared to the current protocol (referred to 
as the Gold Standard). It has been cited that the current protocol is most susceptible to user-
error during emergency situations as it can pose a serious time-threat [60], [64], [69]. 
Therefore, it was determined important to compare the Vial Cap’s disinfection efficiency 
to the Gold Standard in a time-sensitive situation to see if it would have an improved 




operate the Vial Cap when handed the device. This test can determine if the Vial Cap design 
is intuitive and will reveal any design flaws [83]. At the conclusion of usability testing, a 
System Usability Scale (SUS) questionnaire was administered to assess the perceived ease 
of use and user acceptance [76], [84], [85]. User acceptance has a high impact on product 
design requirements, indicating the significance of evaluating the user’s opinions at the 
conclusion of testing [86].  
4.2 Materials and Methods 
4.2.1 Human Study: Sample Size and Setting 
The usability assessment was performed with an approved IRB protocol (PRO-
2021-271) from the Rowan University Institutional Review Board, Glassboro, New Jersey, 
US. Participants were selected through a volunteer-basis recruitment process at Cooper 
University Hospital, Camden, New Jersey, US. A total of 13 participants were selected 
based on the following inclusion criteria: 1) experience with MDVs, 2) nurse at Cooper 
University Hospital, and 3) speak and write English fluently. 13 participants allowed for 
multiple rounds of testing to be performed to allow for design and procedural iterations. It 
has been shown that after the first five participants, about 80% of the usability issues are 
identified, making it important to have a sample size greater than five [87].  
Usability testing was performed with one participant at-a-time to prevent any 
external bias from others. The study duration for the participants is 30 minutes per 
participant. Upon arrival to the testing session, participants were to have completed the 
informed consent form so that they are aware of the circumstances and any associated risks 




4.2.2 Ease-of-Use Test  
The first task of the usability assessment is simulating drawing-up medication from 
an MDV that has the Vial Cap on it. A sterile syringe with no needle was used, and the 
MDV did not contain any liquid medication. This serves to determine the ease of use based 
on first-hand experience and simulated usage with the Vial Cap. The following flow 




Subtask Flow Diagram: Ease of Use Test 
 
 
The measurable outcomes of this test will be based on the completion of each 
subtask. The error and completion rates can be used to determine the overall ease of use of 
the Vial Cap [76]. The completion rate will be based on the success or failure of each 




100%), partial success (coded as 50%), or failure (coded as 0%) [80]. Partial success is 
selected when a participant performs the wrong action but can complete the subtask after 
another attempt without input from the investigator. The error rate (E) is determined by a 
binary system: the user encountered an error (1 = yes) or did not (0 = no) [81].  
4.2.3 Efficiency Test 
The second test of the usability assessment involves a comparison of usage time 
between the Gold Standard and the Vial Cap. A timed simulated medication withdraw will 
be performed by the participants using the Vial Cap and Gold Standard method. For this 
timed task, the participants will be told to complete the medication withdraw as if it were 
a time-pressed situation. This task will be completed and timed for each MDV disinfection 
method. The timed results will provide a direct comparison of efficiency between each 
disinfection method. 
4.2.4 User Acceptance 
To quantify the user satisfaction and acceptance of the Vial Cap, a SUS 
questionnaire will be administered at the conclusion of testing. The SUS questionnaire is 
constructed of ten Likert scale questions and one adjective rating scale question. The Likert 
scale questions probe the user to analyze the positive and negative aspects of the design. 
The answer options are on a scale from one to five with one being ‘Strongly Disagree’ and 
five being ‘Strongly Agree.’ The questionnaire is administered immediately after the 
participants complete testing. The calculated results will provide a SUS score from 0 to 




4.2.5 Data and Statistical Analysis  
The task completion rate (C) is measured as a percentage value for success (coded 
as 100%), partial success (coded as 50%), or failure (coded as 0%) for each subtask [80]. 
Equation 1 was used to calculate the completion rate where ||t|| denotes the number of 
subtasks, 𝐶(𝑠𝑢𝑐) denotes the number of successes, and 𝐶(𝑝𝑎𝑟) denotes the number of 
partial successes [80]: 






∗ 0.5)                (1) 
The error rate (E) is also determined by a binary system: the user encountered an 
error (1 = yes) or did not (0 = no) when completing each subtask [81]. Equation 2 was used 
to calculate the error rate where ||t|| denotes the number of subtasks and e is the number 
of errors:  
𝐸(𝑡) =  
𝑒
||𝑡||
            (2) 
The efficiency was determined by comparing the task duration (T) or the total time 
taken to achieve a particular task at hand [80]. The task duration was measured in seconds 
and the average time for both disinfection methods were compared.  
To calculate the SUS score, the sum was taken from each question (n = 10). Each 
question’s score contribution will range from 0 to 4. In the questionnaire, questions 1, 3, 5, 
7, and 9 the score contribution is the scale position minus 1 [88]. For questions 2, 4, 6, 8, 
and 10, the contribution is 5 minus the scale position [88]. The contributions are summed 
and then multiplied by 2.5 to obtain the overall score (Equation 3) [80]. The SUS score 




  𝑆𝑈𝑆 = 2.5 × [ ∑ (𝑈2𝑛−1 − 1) + (5 − 𝑈2𝑛)
5
𝑛=1 ]                              (3) 
An adjective rating scale will also be included at the end of the questionnaire. The 
variability was determined by calculating the standard deviation or the 95% confidence 
interval (CI). The level of significance used in this study will be 0.05. One-way analysis of 
variance (ANOVA) was used to determine the statistical significance from efficiency 
testing. A one-sided t-test was used to determine the statistical significance of the SUS 
score compared to the ‘excellent’-rated score [81].  
4.3 Results 
4.3.1 Ease of Use  
The ease of use of the Vial Cap was quantified based on the successful completion 
of each subtask required to operate the Vial Cap (Figure 10). Subtask 1 was the most 
difficult with participants having an 84.62% completion rate. One error occurred for two 
participants at the first step of the Vial Cap operation where participants believed the needle 
would be pierced through the cap as opposed to flipping it open. However, the two 
participants were able to successfully figure out how to complete after this error and 
considered to be partial completion. This brings the total for Subtask 1 to be 100% after 









Task Success Distribution for Ease of Use Testing 
 
Note. Data is representative of each subtask completion rates where n = 13 is the number 
of participants completing each subtask of the Vial Cap operation.  
 
4.3.2 Efficiency 
 The Vial Cap’s medication withdraw time when compared to the GS was 
significantly (p = 0.0000279)  faster for MDV disinfection. When comparing the minimum 
disinfection requirements of an MDV during an emergency, the Vial Cap is likely to be 
8.47 ± 3.07 s faster than the GS procedure (mean difference ± 95% confidence interval). 
The average time to simulate withdrawing medication using the Vial Cap was 7.62 ± 0.37 
s and the GS was 16.09  ± 0.60 s. The additional step of sealing the Vial Cap after 




entire Vial Cap process was likely to be 4.18 ± 3.26 s faster than the GS procedure. The 
entire Vial Cap process took an average time of 11.91  ± 0.42 s. 
 
Figure 11 
Vial Cap Efficiency Test Results 
 
Note. Data is representative of the mean ± standard deviation where n = 13 for each timed 
disinfection process. * (p < 0.05); *** (p < 0.001). 
 
4.3.3 User Acceptance 
 The results of the Vial Cap’s SUS were a score of 95.19 ± 5.63, a high result 
compared to the average score of 68 (Figure 12) [87]. 23.08% of participants rated the Vial 
Cap as ‘best imaginable’ and the other 76.92% described the design as ‘excellent’ when 




score to other metric scales for interpreting usability, the Vial Cap can be described as 
‘excellent’ on the adjective rating scale (Figure 12) [88]. The desired outcome of the SUS 
was a score equal to or greater than ‘excellent’ (SUS score of 85) to provide supporting 
evidence of user acceptance. The one-sided t-test revealed statistical significance  
(p = 0.000014) that the Vial Cap’s score is higher than the correlating score for ‘excellent.’  
 
Figure 12 
SUS Questionnaire Results 
 
Note. A) Vial Cap SUS results where data is representative of the mean ± standard 
deviation where n = 13 for total participants. B) HFE scale for comparison of adjective 




 Participant feedback was collected the usability study to provide insight into their 
acceptance of the Vial Cap. A summary of the frequent comments can be found in Table 
2. Important comments to address include comments received about the design such as “it 
was bulky” (n = 6) and that the Vial Cap should be reusable (n = 7) and “needs a way to 
track uses.”  
 
Table 2 
IRB Study Participant Comments 
Comment Comment 
Positive Tone Frequency Negative Tone Frequency 
Efficient and easy to use 13 Cap is bulky 6 
Vial Cap did not get in the way 
during injections  
10 
Vial Cap is not 
stationary/gets in the way 
3 
The Vial Cap should be made 
from a ridge material 
12 
There needs to be a way to 
keep track of uses 
7 
Provides reassurance that a vial 
is disinfected and protected 
3 
Cap needs to remain 









 The usability assessment performed in this work is a useful HFE technique that 
provides insight to a device’s usability and user acceptance [83]. Evaluation of the Vial 
Cap’s ease of use, efficiency, and user satisfaction revealed flaws with the current design 
and insight into the device’s potential as a method of MDV disinfection. From ease of use 
testing, the only task that created difficulty for participants was Subtask 1 which involved 
opening the Vial Cap to reveal the rubber diaphragm for an injection. The error that 
occurred (n = 2 participants) might be related to user practice or the need for design 
improvements [76]. These errors provide diagnostic information related to the device 
design, the user-interface, and perceived usefulness of the Vial Cap [81]. From a design 
perspective, the ‘tab’ meant for flipping the Vial Cap open could be increased in size to 
indicate the cap should be opened before withdrawing. Once the Vial Cap was successfully 
opened, the other subtasks were straightforward and yielded 100% completion. The 
minimal error rate (n = 2) encountered during Vial Cap operation can support the claim 
that the ‘Vial Cap is easy to use.’ The results from this study demonstrated an effective 
operation of the Vial Cap, providing supporting evidence that the device is easy to use [76], 
[89].   
 Efficiency is another important element of a medical device that most often directly 
or indirectly related to cost, safety, and satisfaction [69], [90]. When assessing the Vial 
Cap, it needs to disinfect a vial as or more quickly than the GS protocol to be accepted by 
the intended users [75], [91]. Considering the minimum steps for MDV disinfection 
(disinfecting the vial diaphragm and withdraw), the Vial Cap was significantly (p < 0.001) 




determining factor in an emergency [51], [64]. Even when adding the step of recapping, 
the Vial Cap was still significantly (p < 0.05) faster than the GS procedure. These results 
provide evidence that the Vial Cap can potentially reduce the opportunity for user-related 
errors by increasing the efficiency of MDV disinfection.  
 User acceptance is another critical element of medical device design and validation 
because without user approval, a device would not be successfully implemented in a 
healthcare-setting [92]. The average SUS score was 95.19, correlating to ‘excellent’ 
satisfaction and usability on the adjective rating scale [84], [87], [88]. Mounting evidence 
supports the validity and reliability of the SUS score in extrapolating a device’s usability 
and user acceptance [81], [87], [93]. The reported SUS score can be interpreted as the 
users’ expressing their acceptance and satisfaction with the Vial Cap [87]. Items Q3 and 
Q7 on the SUS questionnaire stated that the system was “easy to use” and users “would 
learn to use this system very quickly.” All 13 participants replied “Strongly Agree” to these 
items, representing satisfaction and likeability of the Vial Cap. The ability of participants 
to overcome an error during cap operation also supports the reliability of the SUS score to 
quantify user acceptance. 
 Comments that were recorded during testing pertained to positive and negative 
aspects of the Vial Cap design. The comment that had the highest frequency (n = 13) was 
that the Vial Cap was “easy and efficient to use.” Participants were accepting and 
enthusiastic about the Vial Cap saying it would “provide reassurance of MDV disinfection” 
and “solves convenience issues with vial disinfection.” Considerations for Vial Cap design 




during injections.” It was observed that the Vial Cap would rotate when inverted for 
withdraw and could become a potential obstruction during use. This design flaw could be 
resolved by using a flexible material, such as thermoplastics like urethane (TPU), that can 
more easily grip the MDV neck and resist rotation when inverted. The Vial Cap’s bulkiness 
can be minimized by reducing the overall cap height and thickness.  
 When engineering the Vial Cap, there are considerations for whether the Vial Cap 
should be reusable or single-use. The participants were asked their preference on this 
subject and it was found that 46% of participants would prefer the Vial Cap to be single-
use while 54% of participants would prefer a reusable device (Table 3).  
 
Table 3 
Single-Use vs Reusable Poll Results 
Single-Use Device Reusable Device 
6 7 
 
There are more design considerations for making the Vial Cap a reusable device. 
The most important concern from the participants was a way to track the cap’s reusability. 
Potential design solutions to track the cap’s usage would be a color-coded label that is 
placed on the Vial Cap that corresponds to its expiration date. Or the Vial Cap could have 
a built-in dial that allows the user to increase the number as the cap is used. The reusability 





 Usability is an important aspect of medical device design to ensure device 
reliability, safety, and performance for both the user and patient [94]. HFE-based design 
considers design aspects such as ease of use, safety, efficiency, and learnability [94]. These 
HFE-based design metrics were quantified using a usability assessment for the Vial Cap 
prototype. Results revealed that the Vial Cap prototype had high usability, acceptability, 
and learnability. A high average SUS score can be related with a high completion rate and 
a significant reduction in disinfection time. User acceptance observed during testing 
provides supporting evidence of the feasibility of the Vial Cap as a new method of MDV 
disinfection.  
 Results from usability testing can act to improve the Vial Cap’s operation and 
increase its acceptance. As future iterations of the Vial Cap are produced, the methods 
outlined in this work can be used to continue testing the device’s usability. FDA guidelines 
of usability testing require usability testing to demonstrate a device can be used by the 
intended users without serious harm [90], [95]. The results from this study have 
demonstrated the ability of the intended users to operate the Vial Cap successfully and 
safely. Furthermore, future usability studies conducted with an improved Vial Cap design 









Vial Cap Effectiveness 
5.1 Introduction 
The characterization of the Vial Cap effectiveness is an important element in the 
cap design because it is the main function of the device. For successful implementation of 
the device in a hospital setting, the cap must meet the required efficacy standards of similar 
products such as pre-saturated towelettes [96]. Engineering and regulatory standards set by 
organizations such as the Environmental Protection Agency (EPA), Food and Drug 
Administration (FDA), Centers for Disease Control (CDC), and American Society for 
Testing and Materials (ASTM) require a minimum level of disinfection for a device to 
permitted on the market [35], [36], [70], [97], [98].  
ASTM Standards E2362-15, E2896-12, and E2967-15 outline specific methods for 
characterizing the bactericidal efficacy of pre-saturated towelettes used for surface 
disinfection. The methods outlined by these standards are relevant to surface contamination 
in hospitals and are reproducible procedures that can be used for testing pre-saturated 
towelettes and similarly, the Vial Cap [70], [99], [100]. These standard testing procedures 
were adapted for the Vial Cap by using an MDV vial as the ‘hard surface’ for disinfection. 
Design elements of the Vial Cap, such as disinfection time, applied force, and sponge 
saturation were tested independently to determine their impact on the Vial Cap’s 
effectiveness. Consideration of these conditions can act to improve the Vial Cap’s current 
design while learning insightful information about the device’s prescribed use. Gram-




prevalence as virulent nosocomial pathogens [101]. ASTM Standard E236-15 also 
recommends testing both species of bacteria to recreate a contaminated surface in a hospital 
setting [70], [102]. Results of testing will provide an understanding of design elements that 
improve the Vial Cap’s effectiveness to be implemented in future design iterations.   
5.2 Materials and Methods 
5.2.1 Bactericidal Efficacy of Vial Cap 
S. aureus (ATCC 35556), P. aeruginosa (ATCC 10145), and E. coli (D31) were 
chosen as Gram-positive and Gram-negative species as the nosocomial pathogens [70], 
[99], [102]. The bacterial species selected are also relatively resistant to drying, allowing 
for ≥108 colony forming units (CFUs) on each dried carrier. Organisms grown from frozen 
stocks were incubated (Incu-Shaker Mini, Benchmark) at 37 ± 1°C and at 225 rotations per 
minute (RMP) for 18 ± 2 h in 3 mL of Luria-Bertani (LB) (Miller) broth. Clear, borosilicate 
glass, pre-assembled MDVs (2 mL volume, 13 mm height) with a butyl stopper and 
aluminum seals were used as the test carriers. This overnight culture was then diluted to 
10-3 CFU/mL for application onto test carrier. Before use, each vial was autoclaved to 
ensure sterility for testing.  
Working under sterile test conditions, a calibrated positive-displacement pipette 
(VWR, RAININ) was used to place 10 µL of the test diluted bacterial suspension on the 
rubber diaphragm of each vial [70], [99]. Once inoculated, the vials were transferred to a 
37 ± 1°C incubator for 30 min to dry the bacterial suspension. While the bacterial 




was soaked with 70% IPA to disinfect prior to use. Uniform 1 x 1-in cotton sponges (VWR) 
were cut with a pair of sterile scissors to be used in the Vial Cap.  
After the bacterial suspension has dried on the test vials, the Vial Caps were loaded 
with 70% IPA (70% Lab Grade, Ward’s Science) and applied on the test vial under specific 
conditions of time, force, and sponge saturation. At the conclusion of testing time, the Vial 
Cap was removed from the test vial and the rubber diaphragm was swabbed with a sterile 
cotton swab moistened with Dulbecco’s phosphate buffered saline (PBS) (pH 7.4, VWR). 
The collected specimen was placed in 2 mL of LB Broth that was vortexed (Mini Vortexer, 
VWR) for 5 s and incubated overnight (24 h) at 37 ± 1°C, 225 RPM. Following overnight 
incubation, the absorbance was measured at 600 nm using a spectrophotometer 
(GENESYS 10S UC-Vis, Thermo Scientific) and serial dilutions (up to 10-4) were 
performed for petri-dish plating. 20 µL of the 10-3 and 10-4 dilutions were plated onto LB 
agar (Difco) plates using sterile glass beads to spread the samples. LB agar plates were 
held upright at room temperature (RT) for 30 ± 2 min prior to plating. Samples were 
incubated (My Temp Mini, Benchmark) at 37 ± 1°C for 24 ± 2 h and counted for any CFUs 
to quantify effectiveness.  
The efficiency of recovery of dried test bacteria from the vials was assessed by 
placing 10 µL of the test inoculum onto a vial, allowing it to dry at 37 ± 1°C for 30 min, 
and eluting it immediately. This sample was used as the ‘positive’ or ‘untreated control’ to 
determine the baseline for calculating the log10 reduction values after Vial Cap application 
[70], [99], [102]. Randomly selected vials were tested for sterility, deemed as the ‘negative 




5.2.1.1 Design Test Conditions. Disinfection times from 5-300 s were employed 
to determine the minimum disinfection time that produces consistent disinfection. A range 
of forces from 0-5 Newtons (N) generated by placing weights on the Vial Cap were used 
to determine the importance of an applied force. Sponge saturations from 0-100% were 
tested to determine the threshold of disinfection for correlation to cap usage. Sponge 
saturation was loaded into the Vial Cap using a scale (VWR) to precisely measure the IPA. 
5.2.2 Passive Evaporation 
The impact of passive evaporation of the Vial Cap prototype was simulated through 
long-term storage of the cap. Dry weight measurements were taken of the assembled Vial 
Cap (0% sponge saturation) and MDV with a calibrated scale  (precision ± 0.01 mg, Mettler 
Toledo). The Vial Cap was loaded with a fully (100%) saturated sponge and immediately 
placed on an MDV. The 100% saturated Vial Cap and MDV were then weighed and 
recorded as the day 0 measurement. The Vial Cap remained sealed while weight 
measurements were taken periodically over a period of 19 days to simulate long-term 
storage. Six MDVs were stored at ambient room conditions and another six vials were 
stored at 37°C and 100% room humidity (RH) in an incubator (NU-8500, NuAire) to 
simulate extreme conditions.  
5.2.3 Simulated-Usage 
Simulated-usage testing was conducted to determine the cap’s evaporation as a 
function of usage. Dry weights were first taken of the assembled Vial Cap (0% sponge 
saturation) and MDV. The Vial Cap was loaded with a fully (100%) saturated sponge and 
immediately placed on an MDV. The 100% saturated Vial Cap and MDV were then 




first remained sealed for 5 min and then was removed for 30 s. The Vial Cap was recapped 
after the 30 s and the weight was recorded. This process was repeated for 60 mins to create 
a model of evaporation on a per-use basis. MDVs were tested at ambient room conditions 
and at 37°C and 100% RH to simulate extreme conditions.   
5.2.4 Data and Statistical Analysis 
 Data analysis for petri-dish plating was analyzed as described in ASTM Standards 
E2362-15 and E2896-12 [70], [99]. The CFU per carrier was calculated by first counting 
the present colonies using ImageJ, the Colony Counter plugin. Equation 4 describes the 
CFU/carrier equation where 10-x is an example of a serial dilution [70]. 
   𝐶𝐹𝑈 𝑐𝑎𝑟𝑟𝑖𝑒𝑟⁄ =
[(𝑎𝑣𝑔.𝐶𝐹𝑈 𝑓𝑜𝑟 10−𝑥) × (𝑉𝑜𝑙.𝑜𝑓 𝑏𝑟𝑜𝑡ℎ)]
[(10−𝑥) × (𝑉𝑜𝑙.𝑝𝑙𝑎𝑡𝑒𝑑) ×(# 𝑜𝑓 𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠 𝑝𝑒𝑟 𝑠𝑒𝑡)]
          (4)               
The log density (LD) of each positive control carriers was calculated to determine 
if an adequate amount of bacteria remained viable after drying (Equation 5) [70].  
𝐿𝐷 = 𝑙𝑜𝑔10(𝐶𝐹𝑈 𝑐𝑎𝑟𝑟𝑖𝑒𝑟)⁄            (5)       
 The log reduction (LR) of each carrier was calculated to determine the reduction of 
bacterial growth after application of the Vial Cap. Equation 6 describes the LR equation 
where 𝑙𝑜𝑔10,𝑝𝑜𝑠 is the LD of the positive control and 𝑙𝑜𝑔10,𝑐𝑎𝑟 is the LD of the selected 
carrier [100].  





Equations 7-8 describe the necessary calculation to determine the CFU/mL for a given 
bacterial suspension (EC, PA, SA) based on the measured absorbance (𝑂𝐷600 ) [103].  
𝐶𝐹𝑈 𝑚𝐿𝐸𝐶⁄ =  𝑂𝐷600  × (1 × 10
9)            (7)    
𝐶𝐹𝑈 𝑚𝐿𝑃𝐴,𝑆𝐴⁄ = 𝑂𝐷600  × (5 × 10
8)         (8)        
 The effectiveness of the Vial Cap can be quantified as a percentage to represent the 
number of bacteria that were eradicated from the test carrier [99]. For example, 100% 
effectiveness represents 0 CFUs remaining on the test carrier. Equation 9 outlines the 
calculation for effectiveness where 𝐶𝐹𝑈 𝑚𝐿𝑐𝑎𝑟⁄  represents the CFU/mL of a test carrier 
and 𝐶𝐹𝑈 𝑚𝐿𝑝𝑜𝑠 ⁄  represents the untreated control.  
𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 (%) = 1 − [
(𝐶𝐹𝑈 𝑚𝐿𝑐𝑎𝑟)⁄
(𝐶𝐹𝑈 𝑚𝐿𝑝𝑜𝑠 )⁄
]                   (9)  
 The sponge saturation of the Vial Cap can be calculated as a percentage to represent 
the remaining disinfectant in the Vial Cap after a period of time or uses. Equation 10 
describes the calculation to determine the sponge saturation where the 𝑊𝑡 is the sample 
recorded at a specific time interval and the 𝑊𝑠 is the weight at 100% saturation or timepoint 
zero.  
𝑆𝑎𝑡𝑢𝑟𝑎𝑡𝑖𝑜𝑛 (%) =  
𝑊𝑡
𝑊𝑆
         (10) 
 ANOVA was used at a 95% level of significance to test statistical differences 
between disinfection time, force, and sponge saturation variables. The variability will be 





5.3.1 Bactericidal Efficacy of Vial Cap 
To determine the basis of each design requirement of the Vial Cap, the baseline 
design conditions first had to be quantified in terms of bactericidal efficacy. The baseline 
test conditions were as follows: 
 
Table 4 
Baseline Test Conditions 
Test Condition Value 
Disinfection Time 300 s 
Sponge Saturation (%) 100% 
Applied Force 0 N 
 
The efficacy of the Vial Cap under these conditions was first measured through an 
absorbance measurement of turbidity. It was determined that the Vial Cap was 100% 
effective against E. coli (± 2.59%) and P. aeruginosa (± 0.69%) and was 95.8% effective 








Baseline Turbidity Results 
 
Note. Data is representative of the mean ± standard deviation where n = 10 for each test 
specimen. 
 
To quantify the disinfection ability of the Vial Cap in accordance with ASTM 
E2362-15 and E2896-12, the quantitative plate method (QPM) was employed. There was 
a 6.08 ± 3.24 log10 reduction in E. coli, 7.97 ± 2.31 log10 reduction in P. aeruginosa, and 
4.82 ± 3.58 log10 reduction in S. aureus (Figure 14). These results can be converted into 
corresponding sterilization values to understand the Vial Cap’s disinfection abilities at 
baseline conditions. There was a 70.08 ± 36.70% total sterilization of E. coli, a 57.53 ± 
42.97% reduction of S. aureus, and 87.47 ± 25.09% reduction of P. aeruginosa. The Vial 




aureus. The maximum log reduction, represented by zero CFUs, is 7-9 log10 reduction 
depending on the test specimen.  
 
Figure 14 
Baseline QPM Results 
 
Note. A) Bacterial log10 reduction of the Vial Cap. The mean is represented by the middle 
crossbar while the error bars are representative of ± 2 standard deviations from the mean 
for n = 10 for each test specimen. The yellow heighted region indicates the range of 
maximum log10 reductions that can be achieved based on n = 6 positive samples. B) 
Efficacy conversion from QPM testing.  
 
5.3.1.1 Disinfection Time.  Preliminary turbidity testing was performed at a variety 
of disinfection times to estimate the Vial Cap’s prescribed disinfection time for use. 
Disinfection times 5 s, 10 s , 30 s, 60 s, and 120 s were tested and compared to the baseline 
disinfection time of 300 s. It was observed that 120 s performed comparable to the Vial 




to 300 s (Figure 15). The consistency of disinfection achieved at 120 s prompted further 
testing with QPM at 120 s to determine if this time can achieve comparable sterilization. 
 
Figure 15 
Disinfection Time Turbidity Results 
 
Note. Data is representative of the mean ± standard deviation where n = 3 for 5s, 10s, 30s, 
and 60s groups, n = 5 for each 120s group,  and n = 10 for each 300s group.   
 
QPM results for a disinfection time of 120 s showed there was a 4.95 ± 3.29 log10 
reduction in E. coli, 6.42 ± 2.98 log10 reduction in P. aeruginosa, and 4.54 ± 2.98 log10 
reduction in S. aureus (Figure 16). This is a 21.77% ± 20.11% decrease in efficacy for E. 
coli, 3.47% ± 21.20% decrease for S. aureus, and 4.13% ± 16.47% decrease for P. 
aeruginosa compared to 300 s. The variability and reduction of sterilization at 120 s 





Disinfection Time QPM Results 
 
Note. A) Bacterial log10 reduction of the Vial Cap at 120s and. The mean is represented by 
the middle crossbar while the error bars are representative of ± 2 standard deviations from 
the mean for n = 5 for each 120s group and n = 10 for each 300s group. The yellow heighted 
region indicates the range of maximum log10 reductions that can be achieved based on n = 






5.3.1.2 Applied Force. Preliminary turbidity testing was used to test applied forces 
of 0.5, 1, 2, and 5 N compared to the baseline of 0 N. Turbidity testing showed that 2 N of 
force had an increase in disinfection consistency compared to 0 N (Figure 17). The Vial 
Cap was 6.15% more effective at 2 N against S. aureus and showed similar disinfection 
capabilities against E. coli and P. aeruginosa. The increase in consistency and sterilization 
prompted further testing QPM at 2 N. 
 
Figure 17 
Applied Force Turbidity Results 
 
Note. Data is representative of the mean ± standard deviation where n = 3 for 0.5N, 1 N, 






Results from the QPM revealed that there was an increase in bacterial reduction 
consistency for all test specimen  at 2 N (Figure 18). There was a 6.30 ± 2.28 log10 reduction 
in E. coli, 7.67 ± 0.00 log10 reduction in P. aeruginosa, and 6.37± 2.62 log10 reduction in 
S. aureus. This is a 20.83% ± 17.96% increase in efficacy for E. coli, 44.12% ± 20.42% 
increase for S. aureus, and 14.33% ± 7.93% increase for P. aeruginosa compared to 0 N. 
It can also be observed that there is a decrease in disinfection variability when a force is 



































Applied Force QPM Results 
 
Note. A) Bacterial log10 reduction of the Vial Cap at 0 N and 2 N. The mean is represented 
by the middle crossbar while the error bars are representative of ± 2 standard deviations 
from the mean for n = 5 for each 2 N group and n = 10 for each 0 N group. The yellow 
heighted region indicates the range of maximum log10 reductions that can be achieved 






5.3.1.3 Sponge Saturation. Sponge saturations of 0%, 25%, 50%, 75%, 80%, 85%, 
and 90% were tested and compared to the baseline of 100% saturation to determine the 
threshold of sterilization. Preliminary turbidity testing revealed a significant (p = 0.0029) 
decrease in effectiveness at 75% saturation for S. aureus (Figure 19). There was a 
significant (p = 0.023) reduction in effectiveness against P. aeruginosa at 25% saturation 
and a significant (p < 1E-05) decrease against E. coli at 0% saturation. At 85% sponge 
saturation, there was no decrease in effectiveness against S. aureus and consistent 
disinfection was maintained compared to 100%. This indicates the threshold of disinfection 
at 85% saturation and a significant decrease in effectiveness at 75% saturation. 
 
Figure 19 
Sponge Saturation Turbidity Results 
 
Note. Data is representative of the mean ± standard deviation where n = 3 for 0%, 25%, 
50%, 80%, and 90% groups, n = 5 for 75% and 85% groups, and n = 10 for each 100% 
group. *p < 0.05,   ** p < 0.01, *** p < 0.001, compared to 100% sponge saturation 




 QPM revealed there was a significant (p = 0.028) decrease in bacterial log10 
reduction at 75% saturation for S. aureus (Figure 20). There was a 6.28 ± 2.28 log10 
reduction in E. coli, 5.44 ± 2.87 log10 reduction in P. aeruginosa, and 0.51 ± 0.69 log10 
reduction in S. aureus. The Vial Cap’s performance significantly decreased for the 
disinfection of S. aureus, resulting in an 88.24%  ±  19.43% decrease in efficacy compared 
to 100% saturation. Alternatively, there was an increase in consistent bacterial log10 
reduction at 85% saturation for all test specimen. The Vial Cap had a 7.13 ± 0.00 log10 
reduction in E. coli, 7.68 ± 0.00 log10 reduction in P. aeruginosa, and 6.35 ± 2.74 log10 
reduction in S. aureus. When compared to the bacterial reduction of S. aureus at 75% 
saturation, there was a significant (p = 0.018) increase in the Vial Cap’s ability to disinfect 



















Sponge Saturation QPM Results 
 
Note. A) Bacterial log10 reduction of the Vial Cap at 100%, 85%, and 75%. The mean is 
represented by the middle crossbar while the error bars are representative of ± 2 standard 
deviations from the mean for n = 5 for 75% and 85% groups and n = 10 for each 100% 
groups. The yellow heighted region indicates the range of maximum log10 reductions that 
can be achieved based on n = 12 positive samples. * p < 0.05. B) Efficacy conversion of 







5.3.2 Passive Evaporation 
 Results from long-term evaporation show that evaporation is evident at the day 1 
timepoint. Resulting in an 18.86 ± 4.85% loss in 70% IPA at ambient conditions and 26.52 
± 5.30% loss at 37°C conditions (Figure 21). Evaporation at ambient room conditions 
decreases overtime while evaporation reaches steady state after about 7 days at 37°C 
storage. These results indicate the Vial Cap prototype is impacted by passive evaporation 
and must be avoided during testing to ensure the desired sponge saturation is tested.  
 
Figure 21 
Passive Evaporation Results  
 
Note. Data is representative of the mean ± standard deviation at each time point where n = 







 To minimize the influence of long-term evaporation during testing, usage testing 
was performed over one hour at five-minute intervals to independently measure the impact 
of usage on evaporation. Simulated-usage testing revealed a 7.76 ± 2.80% loss in sponge 
saturation at ambient room conditions and an 8.82 ± 1.14% loss at 37°C conditions (Figure 
22). Since minimal evaporation was experienced during testing, a simple linear model of 
evaporation was assumed to estimate the Vial Cap’s maximum number of uses. Using the 
Vial Cap’s threshold of effectiveness at 85% sponge saturation, the estimated maximum 



















Simulated-Usage Evaporation Results 
 
Note. A) Simulated-usage evaporation results. Data is representative of the mean ± 
standard deviation at each time point where n = 10 for each timepoint at both environment 









5.4 Discussion  
Baseline testing conditions were needed as comparative data to determine the Vial 
Cap’s design criteria. Testing of the Vial Cap’s disinfection time, applied force, and sponge 
saturation at this stage of prototyping were necessary to gain an insight into the role of each 
design criterion. Baseline testing demonstrated early on that the Vial Cap was the most 
effective against the Gram-negative bacteria, E. coli and P. aeruginosa. These results are 
translatable to other studies performed with pre-saturated towelettes and other common 
surface disinfectants [96], [104]–[106]. For example, in a study comparing disinfectant 
towelettes it was observed that the towelettes had a 0.12-0.80 log10 greater reduction 
against P. aeruginosa than S. aureus for all tested wipes (n = 11) [106]. The reduced 
effectiveness against S. aureus could be related to the bacteria’s ability to survive on 
nonporous surfaces and create biofilms that can protect itself from adverse conditions 
[107].  
 Disinfection time was the first design element addressed to determine if the 
estimated threshold of disinfection was less than 300 s. Preliminary turbidity testing was 
used for bulk testing of the various test conditions to obtain a baseline of disinfection before 
more precise quantification with colony-counting. Turbidity testing showed that 120 s was 
comparable to the disinfection capability at 300 s for all test specimen. S. aureus serves to 
define the benchmark of disinfection for all testing because of its lower efficacy results at 
300 s. QPM results showed that there was a decrease in bacterial reduction and increase 
variability at 120 s compared to 300 s. The decrease in performance could be attributed to 
the reduced contact time that is needed to completely disinfect the vial surface [108]. Since 




could be defined as 300 s or longer. Implementing a longer disinfection time could warrant 
a margin of safety (MOS) that ensures the user the cap will provide adequate disinfection 
when used for at least its prescribed time.  
 Applied force was a relevant design consideration for the Vial Cap because there is 
a crucial role in the mechanical motion of wiping to yield high effectiveness with pre-
saturated towelettes [102], [108]–[110]. The frequency and exerted force of a wiping action 
can profoundly influence the result of surface disinfection [108]. Preliminary turbidity 
testing revealed no significant difference between any applied forces. 2 N of force 
demonstrated an increase in disinfection consistency and therefore was quantified further. 
Results from QPM revealed that there was a decrease is variability at 2 N of force. 
Incorporating an applied force in the Vial Cap design could be advantageous to ensure 
consistent MDV disinfection. Implementing a closure force to the Vial Cap design could 
generate the required applied force. The closure force could be generated through a 
snapping or locking mechanism that secures the Vial Cap in place, a design similar to 
reusable water bottles.  
  The impact of passive evaporation on the Vial Cap prototype was quantified to 
determine its impact on the timing of experiments. It was observed that the Vial Cap is 
greatly impacted by passive evaporation as it experienced a 19-26% loss in disinfectant. 
Trends of evaporation observed in 37°C conditions can be attributed to the tendency of 
PLA to readily absorb moisture and the environment being fully saturated, permitting the 
diffusion of IPA from the sponge [111]. Majority of the Vial Cap’s evaporation can be 




structural defects in an object such as high porosity and poor sealing properties [112]. 
Therefore, it was crucial that testing occurs immediately after loading a Vial Cap prototype 
to minimize the impact of passive evaporation.  
 Another important design criterion of the Vial Cap was the sponge saturation at 
which there is a significant decrease in efficacy. It is expected that as the Vial Cap is used, 
there will be disinfectant loss due to evaporation. To mimic this, the Vial Cap was loaded 
with varying sponge saturations and tested. Turbidity testing revealed that there was a 
significant decrease in effectiveness against S. aureus at 75% sponge saturation. Further 
quantification with QPM confirmed the significant decrease in efficacy at 75% saturation 
for S. aureus. E. coli and P. aeruginosa also had decreasing disinfection consistencies at 
75% sponge saturation. However, comparable results to 100% saturation were achieved 
with 85% sponge saturation for all specimen. This estimates that the sponge saturation 
threshold is 85% to ensure consistent disinfection is maintained with the current prototype. 
To minimize any disinfectant loss due to passive evaporation, simulated-usage 
testing was performed over a period of 60 min. Usage testing revealed a 7-8% loss in 
disinfectant depending on the storage conditions. This loss can be attributed to the exposure 
of the saturated sponge surface area to the environment. When correlating this to efficacy, 
the Vial Cap has an estimated maximum of 25 uses in ambient storage conditions and 20 
in 37°C conditions. This procedure can be used to determine the final Vial Cap’s lifespan, 
important information required by the FDA for the device’s instructions for use (IFU) 
[113]. Additionally, the long-term evaporation procedure described can serve to test the 




Results from testing revealed a major design flaw with the Vial Cap’s susceptibility 
to evaporation. Evaporation during usage is expected and has a minimal impact on the 
present disinfectant compared to long-term storage. Evaporation can be mitigated through 
selection of manufacturing processes that are not susceptible to creating high porosity. 
Precision injection molding offers a potential solution to significantly reduce the Vial 
Cap’s susceptibility to evaporation. Since this manufacturing process is not additive like 
3D printing, it has the ability to mold an object with a high tolerance for precision and 
minimal porosity [115]. Incorporation of recommended design elements and production 
with methods less prone to porosity can increase the Vial Cap’s efficacy for safe and 
effective use.  
5.5 Conclusion 
 Mounting evidence of MDV contamination in healthcare settings has identified a 
user compliance issue with the current disinfection protocol [8]. The Vial Cap offers a 
potential solution to this issue as it continuously disinfects the vial. The efficacy of different 
design elements was quantified using a modified version of ASTM Standard E2362-15 to 
provide a direct comparison to pre-saturated wipes. Results of efficacy testing were used 
to determine important elements of the Vial Cap design that yielded the most reliable 
disinfection capabilities. The disinfection time, applied force, maximum uses were 
estimated from efficacy testing. The disinfection time and maximum uses are to be 
incorporated in the IFU to provide the user with clear information for the safe and effective 
use of the Vial Cap. Quantifying the applied force served to demonstrate the significance 




 Design improvements attained from efficacy testing can improve the Vial Cap’s 
ability to consistently achieve 100% bacterial reduction for the tested nosocomial 
pathogens as well as other virulent ones such as MRSA, Clostridium difficile, and 
vancomycin-resistant enterococci [116]. Future iterations of the device will continue to 
undergo the testing methods described in this work to define the Vial Cap’s efficacy. With 
the proper design changes, the Vial Cap has the potential to reduce user-related errors with 

















Project Summary and Future Work 
6.1 Project Summary 
 The aims of this research were to evaluate the usability and efficacy of the Vial Cap 
through iterative experimental methods that can be used in final testing of the device. HFE 
design techniques were utilized for determining the user needs, design flaws, and to assess 
the device’s usability [11], [69]. The Vial Cap’s ease of use, efficiency, and user acceptance 
were measured through a usability test with the intended users. Results from usability 
testing revealed that the Vial Cap had high learnability, acceptability, and usability. Such 
successful testing results give an indication of the perceived usefulness and acceptance of 
the current prototype as well as feedback for design improvement [83], [89].  
 Evaluation of the Vial Cap’s efficacy was a critical element to offer evidence that 
the device is as effective as pre-saturated wipes used in the current protocol. For the 
purposes of this research, the disinfection time, applied force, and maximum uses were 
investigated to determine their impact on effectiveness. Results provided the estimated 
disinfection time and prescribed uses needed to ensure consistent sterilization. Design 
considerations such as adding an applied force were also noted to improve disinfection 
consistency. Efficacy testing provides valuable insight into the current state of the Vial Cap 
prototype and recommendations for final design changes. The impact of this research 
identified the need for improved MDV disinfection methods that are less susceptible to 




Cap can prove to be an advantageous solution to this issue and improve overall patient 
care.  
6.2 Future Work 
 These results are the first to identify the potential of the Vial Cap as a new method 
of MDV disinfection. The methods outlined in this research can be used to evaluate future 
iterations of the Vial Cap design. Potential avenues forward with the Vial Cap would be 
testing its effectiveness against other more virulent nosocomial pathogens such as MRSA, 
Clostridium difficile, Canadian albicans, and viruses such as adenoviruses [101]. The Vial 
Cap also have the potential to be marketed for at-home patients and caregivers. A similar 
usability test could be given to these individuals to determine if the practicality of the Vial 
Cap for patients who give self-injections. An additional design consideration could be the 
incorporation of a wiping motion in the Vial Cap application. In addition to pressure, 
literature suggests the importance of a mechanical wiping motion to effectively remove 
microbial contamination on a hard surface [96], [108]. The results from this research also 
provide guidance for the selecting the proper packaging that prevents passive evaporation. 
Overall, the impact of this research allows for the continual testing of the Vial Cap to better 
its performance for implantation into the healthcare field that will ultimately improve 
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Please check the box that reflects your immediate response to each statement. Don’t think too 
long about each statement. Make sure you respond to every statement. If you don’t know how 
to respond, simply check box “3.” 
 
1. I think that I would like to use this product frequently. 
 
2. I found the product unnecessarily complex. 
 
3. I thought the product was easy to use.  
 
4. I think that I would need the support of a technical 
 person to be able to use this product. 
5. I found the various functions in the product were well 
integrated. 
6. I thought there was too much inconsistency in this 
product. 
 
7. I imagine that most people would learn to use this  
product very quickly. 
 
8. I found the product very awkward to use. 
 
9. I felt very confident using the product. 
 
10. I needed to learn a lot of things before I could get  
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Appendix B  





Positive (n = 1) Negative (n = 1) 
Reduces confusion Top heavy design 
Vial Cap allows for easier grip of vial 
Skeptical of disinfection, would still use 
IPA wipe after removal of Vial Cap 
Could be cost-effective in the long-term Hinge is bulky 
Liked clicking sound of plastic when 
sealing Vial Cap to ensure it is closed 
Prefer cap to be a flexible material 
 
 
 
 
 
